Orphan drugs: rising to the challenge to ensure a better future for 30 million patients in Europe
As the number of drugs for rare diseases grows, there is also growing concern that increasing costs will put an excessive strain on healthcare budgets. EURORDIS has released a paper, which uses mathematical models to predict the number of orphan drugs that will enter the market in the next ten years and their economic impact. The paper dispels the myth of a ’tidal wave’ of orphan drugs flooding the market and of their potential overwhelming cost to society.